GlaxoSmithKline plc (NYSE:GSK) Shares Purchased by Sigma Planning Corp

Sigma Planning Corp increased its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 6.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 54,720 shares of the pharmaceutical company’s stock after purchasing an additional 3,416 shares during the period. Sigma Planning Corp’s holdings in GlaxoSmithKline were worth $2,179,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital International Investors lifted its holdings in shares of GlaxoSmithKline by 12.9% during the first quarter. Capital International Investors now owns 19,889,711 shares of the pharmaceutical company’s stock worth $709,866,000 after purchasing an additional 2,271,163 shares during the period. Fisher Asset Management LLC lifted its holdings in GlaxoSmithKline by 3.1% in the second quarter. Fisher Asset Management LLC now owns 17,547,991 shares of the pharmaceutical company’s stock valued at $698,761,000 after acquiring an additional 526,006 shares during the period. Black Creek Investment Management Inc. lifted its holdings in GlaxoSmithKline by 4.8% in the second quarter. Black Creek Investment Management Inc. now owns 9,086,870 shares of the pharmaceutical company’s stock valued at $361,839,000 after acquiring an additional 418,371 shares during the period. JTC Employer Solutions Trusteee Ltd acquired a new stake in GlaxoSmithKline in the second quarter valued at $295,332,000. Finally, BNP Paribas Arbitrage SA lifted its holdings in GlaxoSmithKline by 46,232.9% in the second quarter. BNP Paribas Arbitrage SA now owns 6,011,230 shares of the pharmaceutical company’s stock valued at $239,367,000 after acquiring an additional 5,998,256 shares during the period. 12.25% of the stock is owned by hedge funds and other institutional investors.

GSK opened at $38.80 on Thursday. The company has a debt-to-equity ratio of 0.95, a current ratio of 0.82 and a quick ratio of 0.53. The stock has a market capitalization of $104.47 billion, a price-to-earnings ratio of 16.37, a price-to-earnings-growth ratio of 2.10 and a beta of 0.70. The business has a 50-day moving average of $40.03 and a two-hundred day moving average of $39.20. GlaxoSmithKline plc has a 12 month low of $33.26 and a 12 month high of $42.68.

GlaxoSmithKline (NYSE:GSK) last posted its quarterly earnings results on Wednesday, July 28th. The pharmaceutical company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.54 by $0.25. The company had revenue of $11.31 billion during the quarter, compared to analysts’ expectations of $10.55 billion. GlaxoSmithKline had a return on equity of 26.21% and a net margin of 13.40%. Equities research analysts anticipate that GlaxoSmithKline plc will post 2.77 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 7th. Shareholders of record on Friday, August 20th were issued a $0.523 dividend. This represents a $2.09 annualized dividend and a yield of 5.39%. The ex-dividend date of this dividend was Thursday, August 19th. GlaxoSmithKline’s dividend payout ratio (DPR) is 68.46%.

GSK has been the subject of a number of recent analyst reports. UBS Group reissued a “neutral” rating on shares of GlaxoSmithKline in a report on Monday, September 20th. Morgan Stanley restated an “equal weight” rating on shares of GlaxoSmithKline in a research report on Thursday, October 7th. Barclays reiterated an “underweight” rating on shares of GlaxoSmithKline in a research report on Monday, July 19th. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a research report on Friday, August 20th. Finally, Zacks Investment Research cut GlaxoSmithKline from a “hold” rating to a “sell” rating and set a $41.00 price objective for the company. in a research report on Tuesday, July 20th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $41.00.

GlaxoSmithKline Profile

GlaxoSmithKline Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation.

See Also: Does a trade war provide a risk to the global economy?

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.